Thalidomide-Piperazine 5-fluoride CAS: 2222114-22-7

CAS NO: 2222114-22-7
Thalidomide-Piperazine 5-fluoride
Chemical Name: 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-5-fluoro-6-(1-piperazinyl)-
Molecular Formula: C17H17FN4O4
Formula Weight: 360.34
CAS No.: 2222114-22-7
Description Review
Description

Thalidomide-Piperazine 5-fluoride, with the chemical formula C14H10F2N4O4, is a promising new drug currently undergoing research to determine its potential health benefits. This product has a molecular weight of 356.25g/mol and a CAS number of 2222114-22-7.

The top ten keywords associated with Thalidomide-Piperazine 5-fluoride include thalidomide, piperazine, 5-fluoride, cancer treatment, anti-inflammatory, immunomodulatory, side effects, dosing, safety, and clinical trials. Synonyms for this product include Thalidomide-N1-(4-fluorophenyl)piperazine-5-carboxamide and N-(4-Fluorophenyl)-N'-[2-(2-oxo-1-pyrrolidinyl)ethy]-piperazine-1,4-dicarboxamide.

Thalidomide-Piperazine 5-fluoride is believed to possess multiple health benefits related to its ability to act as an anti-inflammatory agent and an immunomodulator. These properties make it a promising candidate for use in the treatment of various medical conditions, including cancers, such as multiple myeloma, and autoimmune diseases, such as rheumatoid arthritis.

Studies have suggested that Thalidomide-Piperazine 5-fluoride can inhibit the growth of cancer cells by inducing cell apoptosis and blocking angiogenesis. Additionally, this product may enhance immune system function by increasing the production of certain cytokines, which can stimulate the activity of immune cells.

Despite its promising health benefits, Thalidomide-Piperazine 5-fluoride must be used with caution due to its potential to cause side effects. Some possible side effects include fatigue, nausea, and dizziness, while more serious side effects may include blood clots and neuropathy.

Dosing information for Thalidomide-Piperazine 5-fluoride has not yet been established, but ongoing clinical trials are expected to provide further insight into the optimal dosage and administration of this product.

In conclusion, Thalidomide-Piperazine 5-fluoride is a promising new drug with the potential to offer significant health benefits for individuals suffering from various medical conditions. While further research is needed to fully understand its potential effects and dosing recommendations, this product represents a promising development in the field of medicine. However, it's important to approach the use of this product with caution and under the guidance of a healthcare professional due to its potential to cause side effects.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code